Galantamine in Alzheimer’s disease

References

• Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet366, 2112–2117 (2005).
   PubMed Web of Science ®Google Scholar
• World Health Organisation. World Health Report 2003 – Shaping the Future. WHO, Geneva, Switzerland (2003).
   Google Scholar
• Coma-Herrera A, Wittenberg R, Pickard L, Knapp M. MRC-CFAS. Cognitive impairment in older people: its implications for future demands for services and costs. In: Report to the Alzheimer’s Research Trust, PSSRU Discussion Paper. London School of Economics, London, UK 1728, (2005).
   Google Scholar
• Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science217, 408–414 (1982).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendation. Am. J. Geriatr. Psychiatry11, 131–145 (2003).
   PubMed Web of Science ®Google Scholar
• Kueenburg B, Czollner L, Froehlich J, Jordis U. Development of a pilot scale process for the anti-alzheimer drug (-)-galanthamine using large-scale phenolic oxidative coupling and crystallisation-induced chiral conversion. Org. Progress Res. Dev.3, 425–431 (1999).
   Google Scholar
• Marco-Contelles J, doCarmo Carreiras MDC, Rodriguez C et al. Synthesis and pharmacology of galantamine. Chem. Rev.106, 116–133 (2006).
   PubMed Web of Science ®Google Scholar
• Farlow MR. Clinical pharmacokinetics of galantamine. Clin. Pharmacokinet.42(15), 1383–1392 (2003).
   PubMed Web of Science ®Google Scholar
• Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer’s dementia. Drug Disc. Today1, 53–59 (1996).
   Web of Science ®Google Scholar
• Samochocki M, Hoffle A, Fehrenbacher A et al. Galantamine is an allosteric potentiating ligand of neuronal nicotinic but not of muscarenic acetylcholine receptors. J. Pharmacol. Exp. Ther.305, 1024–1036 (2003).
   PubMed Web of Science ®Google Scholar
• Arthur D, Levin ED. Chronic inhibition of α4β2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response. Psychopharmacology16, 140–145 (2002).
   Google Scholar
• Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur. J. Pharmacol.393, 141–146 (2000).
   PubMed Web of Science ®Google Scholar
• Woodruff-Pak DS, Vogel RW, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc. Natl Acad. Sci. USA98, 2089–2094 (2001).
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Pereira EF, Mike A et al. Neuronal nicotinic receptors in synaptic functions in human and rats: physiological and clinical relevance. Behav. Brain Res.113, 131–141 (2000).
   PubMed Web of Science ®Google Scholar
• Reminyl® (galantamine), product information. Janssen–Cilag Pty Ltd, NSW, Australia (2007).
   Google Scholar
• Bachus R, Bickel U, Thomsen T et al. The O-demethylation of the anti-dementia drug galantamine is catalysed by cytochrome P450 2D6. Pharmacogenetics9, 661–668 (1999).
   PubMedGoogle Scholar
• McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology4, 939–944 (1984).
   Web of Science ®Google Scholar
• Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer’s disease. Am. J. Psychiatry141, 1356–1364 (1984).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Olin JT, Doody RS et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADC-CGIC). Alzheimer Dis. Assoc. Disord.11, S22–S32 (1997).
   Google Scholar
• Gelinas I, Gauthier L. McIntyre M et al. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am. J. Occup. Ther.53, 471–481 (1999).
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennet D, Sano M et al. Alzheimer’s Disease Cooperative Study: an inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis. Assoc. Disord.11, S33–S39 (1997).
   PubMed Web of Science ®Google Scholar
• Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology48(Suppl. 6), S10–S16 (1997).
   PubMed Web of Science ®Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment (review). Cochrane Database Sys. Rev. (1) CD001747 (2006).
   Google Scholar
• Rockwood K, Mintzer J, Truyen L et al. On behalf of the Galantamine International-2 Study Group. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J. Neurol. Neurosurg. Psychiatry71, 589–595 (2001).
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Murry J. Galantamine: a randomised, double-blind, dose comparison in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry16, 852–857 (2001).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC et al. Galantamine USA-10 Study Group. A 5-month, randomised, placebo-controlled trial of galantamine in AD. Neurology54(12), 2261–2276 (2000).
   PubMedGoogle Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Br. Med. J.321, 1445–1449 (2000).
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine USA-1 Study Group. Galantamine in AD: a6-month randomised placebo-controlled trial with a 6-month extension. Neurology54(12), 2261–2276 (2000).
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable Vascular dementi and Alzheimer’s disease combined with cerebrovascular disease. A randomised trial. Lancet359, 1283–1290 (2002).
   PubMed Web of Science ®Google Scholar
• Brodaty H, Corey-Bloom J, Potocnik FCV et al. Galantamine prolonged-release formation in the treatment of mild to moderate Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.20(2–3), 120–132 (2005).
   PubMed Web of Science ®Google Scholar
• Stern RG, Mohs RC, Davidson M et al. A study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry151(3), 390–394 (1994).
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Truyen L et al. The cognitive benefits of galantamine are sustained for at least 36 months: a long term extension trial. Arch. Neurol.61, 252–256 (2004).
   PubMed Web of Science ®Google Scholar
• Pirttila T, Wilcock G, Truyen L, Damaraju V. Long-term efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre trial. Eur. J. Neurol.11, 734–741 (2004).
   PubMed Web of Science ®Google Scholar
• Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer’s disease taking galantamine for up to 48 months. Int. J. Geriatr. Psychiatry (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. Br. Med. J.331, 321–327 (2005).
   PubMed Web of Science ®Google Scholar
• Birks J, Harvey R. The efficacy of donepezil for mild and moderate Alzheimer’s disease. Cochrane Database Sys. Rev.1, CD001190 (2005).
   Google Scholar
• Birks J, Grimley Evans J, Iakividou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. Cochrane Database Sys. Rev.4, CD001191 (2005).
   Google Scholar
• Clegg A, Bryant J, Nicholson T et al. Clinical and cost–effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. Int. J. Technol. Assess Health Care18(13), 497–507 (2002).
   PubMedGoogle Scholar
• Loveman E, Green C, Kirby J et al. The clinical and cost–effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol. Assess.10(1), iii–iv, ix–xi, 1–160 (2006).
   Web of Science ®Google Scholar
• O’Brien JT. NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom? Lancet Neurol.5(12), 994–996 (2006).
   PubMedGoogle Scholar
• Fossey J, Lee L, Ballard C. Dementia care mapping as a research tool for measuring quality of life in care setting: psychometric properties. Int. J. Geriatr. Psychiatry17, 1064–1070 (2002).
   PubMed Web of Science ®Google Scholar
• Smith SC, Lamping DL, Banerjee S et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol. Assess.9, 10 (2005).
   Google Scholar
• Gestios D, Caro JJ, Caro G et al. Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in Canada. Neurology57, 972–978 (2001).
   PubMedGoogle Scholar
• Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology43, 2412–2414 (1993).
   PubMed Web of Science ®Google Scholar
• Department of Health and Ageing, Australian Government. Pharmaceutical Benefit Advisory Committee (PBAC) Recommendations for the Use of Anticholinesterases in Alzheimer’s Disease (2005).
   Google Scholar
• Jones RW, Soininen H, Hager K et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer’s disease. Int. J. Geriatr. Psychiatry20(1), 85–87 (2004).
   Google Scholar
• Bullock R, Truyen L. Not all head-to-head trials are created equal: results from an open-label, short-term study seem inconsistent with previous donepezil literature. Int. J. Geriatr. Psychiatry20, 85–87 (2005).
   PubMedGoogle Scholar
• Danysz W, Parsons CG, Mobius H-J et al. Neuroprotective and symptomatological action of mementine relevant for Alzheimer’s disease- a unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res.2, 85–97 (2000).
   PubMed Web of Science ®Google Scholar
• Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Sys. Rev.2, CD003154 (2005).
   Google Scholar
• Wilkinson D, Anderson HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.24, 138–145 (2007).
   PubMed Web of Science ®Google Scholar
• Dantoine T, Auriacombe S, Sarazin M et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract.60(1), 110–118 (2006).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil: a randomised controlled trial. JAMA291, 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Zhao X, Marszalec W, Toth PT et al.in vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology51, 1181–1191 (2006).
   PubMedGoogle Scholar
• Aracava Y, Pereira EFR, Maelicke A, Albuquerque EX. Memantine blocks α7 nicotenic actylcholine receptors more potently than NMDA receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther.312, 1195–1205 (2005).
   PubMed Web of Science ®Google Scholar